Efficacy, safety and prognostic factors analysis of first-line icotinib treatment in advanced non-small cell lung cancer patients with mutated EGFR | Zendy

AI Assistant Blog Pricing

Open Access

Efficacy, safety and prognostic factors analysis of first-line icotinib treatment in advanced non-small cell lung cancer patients with mutated EGFR

Author(s) -

Aimi Huang,

Qing Shen,

Xiaolu Yu,

Huimin Wang,

Chunlei Shi,

Baohui Han,

Aiqin Gu

Publication year - 2018

Publication title -

translational cancer research

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.254

H-Index - 30

eISSN - 2219-6803

pISSN - 2218-676X

DOI - 10.21037/tcr.2018.05.30

Subject(s) - medicine , oncology , lung cancer

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Download on the

Discover

Explore

Copyright Knowledge E © 2026. All Rights Reserved.